Loading...
Market
Global Response to US Scrutiny on Chinese Biotechs by 2024 End
5
Resolution / Starting Odds
Support U.S. Actions • 33%
Oppose U.S. Actions • 33%
Remain Neutral • 34%
Official government statements or credible international news sources
Story
U.S. Increases Scrutiny on Chinese Biotech, Targets WuXi AppTec
Apr 16, 2024, 01:16 AM
Western drugmakers are urgently seeking alternative suppliers in response to the U.S. government's increased scrutiny of Chinese biotechnology firms, specifically targeting Shanghai-based WuXi AppTec as a 'biotechnology company of concern.' This action is part of the broader BIOSECURE Act, which has been described by a global lawyer as the 'elephant in the room' for companies considering deals with Chinese biotechs. The heightened scrutiny is influencing out-licensing deals, which are currently a significant opportunity for Chinese biotech firms. Additionally, U.S. lawmakers have expressed national security concerns, aiming to sever connections between major Chinese biotech firms and U.S. pharmaceutical interests, particularly those involved in developing treatments for diseases such as cancer, cystic fibrosis, and HIV.
View original story
Similar markets
Follow U.S. policy • 33%
Reject U.S. policy • 33%
Stay neutral • 33%
More firms investigated • 25%
Sanctions imposed • 25%
No significant actions • 25%
Other actions • 25%
UN resolution condemning the act • 25%
Increased scrutiny on U.S. activities • 25%
No significant reaction • 25%
Increased support for China's initiatives • 25%
Condemnation by WHO • 33%
Condemnation by ASEAN • 33%
No formal condemnation • 33%
Increased scrutiny and sanctions • 25%
Diplomatic negotiations without sanctions • 25%
No change in current policies • 25%
Enhanced cooperative scientific investigation • 25%
No significant reaction • 33%
Official statements of concern • 33%
Diplomatic actions or sanctions • 33%
No significant international reaction • 34%
Economic or trade measures against the U.S. • 33%
Supportive statements or actions from other countries • 33%
Yes • 50%
No • 50%
Significant decline in market value • 33%
Minor impact on market value • 33%
No impact on market value • 34%
US imposes sanctions • 33%
EU imposes sanctions • 33%
No major actions taken • 34%
Support • 33%
Criticism • 33%
Neutral • 33%
Natural origin • 33%
Lab leak • 33%
Inconclusive • 33%